Role of the CDKN2A locus in patients with multiple primary melanomas.

PURPOSE We have studied a consecutive case series of patients with multiple primary melanoma (MPM) for the involvement of the melanoma susceptibility loci CDKN2A and CDK4. PATIENTS AND METHODS One hundred four MPM patients (81 patients with two primary melanomas, 14 with three, five with four, one with five, two with six, and one with seven) were included. RESULTS Seven different CDKN2A germline mutations were identified in 17 patients (16.3%). In total, we identified 15 CDKN2A exon 2, one exon 1alpha missense mutation, and one exon 1beta frameshift mutation. The age of onset was significantly lower and the number of primary melanomas higher in patients with mutations. CDKN2A mutations were more frequent in patients with familial history of melanoma (35.5%) compared with patients without (8.2%), with a relative risk (RR) of 4.32 (95% CI, 1.76 to 10.64; P = .001), and in patients with more than two melanomas (39.1%) compared with patients with only two melanomas (10%) with an RR of 3.29 (95% CI, 1.7 to 6.3; P = .002). The A148T polymorphism was more frequent in patients with MPMs than in the control population (P = .05). A variant of uncertain significance, A127S, was also detected in one patient. No CDK4 mutations were identified, suggesting that it has a low impact in susceptibility to MPM. CONCLUSION MPM patients are good candidates for CDKN2A mutational screening. These patients and some of their siblings should be included in a program of specific follow-up with total body photography and digital dermoscopy, which will result in the early detection of melanoma in this subset of high-risk patients and improve phenotypic characterization.

[1]  David Hogg,et al.  Mutation of the CDKN2A 5' UTR creates an aberrant initiation codon and predisposes to melanoma , 1999, Nature Genetics.

[2]  D. Stoppa-Lyonnet,et al.  Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group. , 1998, Human molecular genetics.

[3]  S. Menzies,et al.  Short-term digital surface microscopic monitoring of atypical or changing melanocytic lesions. , 2001, Archives of dermatology.

[4]  A. Goldstein,et al.  Sporadic multiple primary melanoma cases: CDKN2A germline mutations with a founder effect , 2001, Genes, chromosomes & cancer.

[5]  M. Tucker,et al.  CDKN2A mutations in multiple primary melanomas. , 1998, The New England journal of medicine.

[6]  A. Halpern.  Total body skin imaging as an aid to melanoma detection. , 2003, Seminars in cutaneous medicine and surgery.

[7]  X. Estivill,et al.  Inherited susceptibility to several cancers but absence of linkage between dysplastic nevus syndrome and CDKN2A in a melanoma family with a mutation in the CDKN2A (P16INK4A) gene , 1997, Human Genetics.

[8]  P. Aegerter,et al.  Is dermoscopy (epiluminescence microscopy) useful for the diagnosis of melanoma? Results of a meta-analysis using techniques adapted to the evaluation of diagnostic tests. , 2001, Archives of dermatology.

[9]  D. Elder,et al.  Multiple primary melanoma revisited , 2002, Cancer.

[10]  D. Bishop,et al.  A germline deletion of p14(ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family. , 2001, Human molecular genetics.

[11]  M. Piepkorn,et al.  Melanoma genetics: an update with focus on the CDKN2A(p16)/ARF tumor suppressors. , 2000, Journal of the American Academy of Dermatology.

[12]  J. Naeyaert,et al.  Clinical practice. Dysplastic nevi. , 2003, The New England journal of medicine.

[13]  J. Hansson,et al.  CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas. , 2000, Cancer research.

[14]  B. Peters,et al.  Analysis of the p16 gene, CDKN2, in 17 Australian melanoma kindreds. , 1995, Oncogene.

[15]  A M Goldstein,et al.  Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. , 1995, The New England journal of medicine.

[16]  X. Estivill,et al.  CDKN2A mutations in Spanish cutaneous malignant melanoma families and patients with multiple melanomas and other neoplasia , 1999, Journal of medical genetics.

[17]  X. Estivill,et al.  Retention of the CDKN2A locus and low frequency of point mutations in primary and metastasic cutaneous malignant melanoma , 1998, International journal of cancer.

[18]  J. Malvehy,et al.  A single Mediterranean, possibly Jewish, origin for the Val59Gly CDKN2A mutation in four melanoma-prone families , 2003, European Journal of Human Genetics.

[19]  N. Basset-Seguin,et al.  Germline and somatic mutations of the INK4a-ARF gene in a xeroderma pigmentosum group C patient. , 2002, The Journal of investigative dermatology.

[20]  J. A. Bishop,et al.  A deep intronic mutation in CDKN2A is associated with disease in a subset of melanoma pedigrees. , 2001, Human molecular genetics.

[21]  J. Malvehy,et al.  A melanoma-associated germline mutation in exon 1β inactivates p14ARF , 2001, Oncogene.

[22]  J. Struewing,et al.  A single genetic origin for the G101W CDKN2A mutation in 20 melanoma-prone families. , 2000, American journal of human genetics.

[23]  A. Goldstein,et al.  High prevalence of the G101W germline mutation in the CDKN2A (P16(ink4a)) gene in 62 Italian malignant melanoma families. , 2002, American journal of medical genetics.

[24]  H. Haenssle,et al.  Results of a surveillance programme for patients at high risk of malignant melanoma using digital and conventional dermoscopy , 2004, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[25]  D. Duffy,et al.  CDKN2A variants in a population-based sample of Queensland families with melanoma. , 1999, Journal of the National Cancer Institute.

[26]  H. Kittler,et al.  Follow-up of melanocytic skin lesions with digital epiluminescence microscopy: patterns of modifications observed in early melanoma, atypical nevi, and common nevi. , 2000, Journal of the American Academy of Dermatology.

[27]  S. Antonarakis,et al.  Mutation nomenclature extensions and suggestions to describe complex mutations: A discussion , 2000 .

[28]  G. Mann,et al.  CDKN2A (P16INK4a) and CDK4 mutation analysis in 131 Australian melanoma probands: Effect of family history and multiple primary melanomas , 1999, Genes, chromosomes & cancer.

[29]  D. Bishop,et al.  Germline mutations of the CDKN2 gene in UK melanoma families. , 1997, Human molecular genetics.

[30]  K. Isselbacher,et al.  Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[31]  W. Clark,et al.  Germline p16 mutations in familial melanoma , 1994, Nature Genetics.

[32]  X. Estivill,et al.  Mutational analysis within the 3' region of the PKD1 gene. , 1999, Kidney international.

[33]  N. Hayward,et al.  Mutations of the CDKN2/p16INK4 gene in Australian melanoma kindreds. , 1995, Human molecular genetics.

[34]  C. D. Edwards,et al.  A novel p16INK4A transcript. , 1995, Cancer research.

[35]  Paolo Carli,et al.  Addition of dermoscopy to conventional naked-eye examination in melanoma screening: a randomized study. , 2004, Journal of the American Academy of Dermatology.

[36]  A. Howell,et al.  Germline mutation of ARF in a melanoma kindred. , 2002, Human molecular genetics.

[37]  R. MacKie,et al.  CDKN2A germline mutations in U.K. patients with familial melanoma and multiple primary melanomas. , 1998, The Journal of investigative dermatology.

[38]  Å. Borg,et al.  Novel germline p16 mutation in familial malignant melanoma in southern Sweden. , 1996, Cancer research.

[39]  T. Hamilton,et al.  Multiple primary melanomas. , 1998, Journal of the American Academy of Dermatology.

[40]  J. Malvehy,et al.  Follow-up of melanocytic skin lesions with digital total-body photography and digital dermoscopy: a two-step method. , 2002, Clinics in dermatology.

[41]  J. Barrett,et al.  An assessment of the CDKN2A variant Ala148Thr as a nevus/melanoma susceptibility allele. , 2002, The Journal of investigative dermatology.